ALPIDEM

/static/temp/default.svg

Search structure


Synonyms	Alpidem SL 80.0342-00 SL-80.0342-00
Status
Molecule Category	UNKNOWN
UNII	I93SC245QZ
EPA CompTox	DTXSID8049046


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JRTIDHTUMYMPRU-UHFFFAOYSA-N
Smiles	CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12
InChI	InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H23Cl2N3O
Molecular Weight	404.34
AlogP	5.5
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	7.0
Polar Surface Area	37.61
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	27.0

Bioactivity

Mechanism of Action	Action	Reference
Translocator protein partial agonist	PARTIAL AGONIST	PubMed PubMed PubMed


Protein: Translocator protein Description: Translocator protein Organism : Homo sapiens P30536 ENSG00000100300

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Ion channel Ligand-gated ion channel GABA-A receptor	-	26-28	-	-	28
Membrane receptor	-	7-8	-	1-7	-
Secreted protein	-	-	2000	-	-
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	9155-9200	-	-	-

Assay Description	Organism	Bioactivity	Reference
Percent inhibition of rat benzodiazepine receptor assayed using [3H]-flumazenil radioligand at 10 um concentration	None	28.0 %
Binding affinity to peripheral benzodiazepine receptors using [3H]-PK11195 radioligand in rat kidney mitochondrial membrane	Rattus norvegicus	7.0 nM
Displacement of Ro 5-4864 from peripheral (renal cell) Benzodiazepine receptor	Rattus norvegicus	7.9 nM
Displacement of [3H]flunitrazepam from rat brain GABA-A Benzodiazepine receptor	Rattus norvegicus	26.0 nM
Binding affinity against central benzodiazepine receptor(CBR).	None	28.0 nM
Binding affinity against peripheral benzodiazepine receptor( PBR).	None	7.0 nM
Displacement of [3H]PK 11195 from peripheral-type benzodiazepine receptor in rat kidney mitochondrial membranes	Rattus norvegicus	0.5 nM
Displacement of [3H]PK11195 from translocator protein in rat kidney mitochondrial membrane	Rattus norvegicus	0.5 nM
Displacement of [3H]PK11195 from TSPO in rat kidney mitochondrial membranes by competitive binding assay	Rattus norvegicus	0.5 nM
Displacement of [3H]flumazenil from central benzodiazepine receptor in rat cerebral cortex membranes at 10 uM after 90 mins by competitive binding assay	Rattus norvegicus	0.0 %
Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay	Rattus norvegicus	100.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-4.6 %
Inhibition of TSPO (unknown origin)	Homo sapiens	0.5 nM		Inhibition of TSPO (unknown origin)	Homo sapiens	7.9 nM
Inhibition of CBR (unknown origin)	Homo sapiens	26.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	4.727 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.27 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.27 %

Related Entries

Cross References

Resources	Reference
ChEBI	135649
ChEMBL	CHEMBL54349
DrugCentral	134
FDA SRS	I93SC245QZ
PubChem	54897
SureChEMBL	SCHEMBL122619
ZINC	ZINC000000599598

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).